HOME > BUSINESS
BUSINESS
- MAA for Lurasidone Accepted in Australia: DSP
April 16, 2013
- Hisamitsu Sales Up 3.6% Helped by Mohrus Tape Sales Recovery
April 15, 2013
- Over Half of Domestic, Foreign-Affiliated Drug Makers Hired Fewer New Graduates This Year: Survey
April 15, 2013
- 11 Drug Makers to Increase, 11 to Decrease Hiring Next Year; Mid-Sized Companies Most Optimistic on Hiring
April 15, 2013
- Astellas to Conduct Interim Analysis for PIII Study of Enzalutamide in mCRPC within 2013
April 15, 2013
- Santen to Disclose Payments to Patient Groups in FY2014
April 15, 2013
- Pfizer Japan Launches Intestinal Amebiasis Treatment on April 12
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
- Daiichi Sankyo Sets Up Office of New Company Specialized in DMD Treatments
April 12, 2013
- Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
- Sanofi K.K. Sales Grew 5.7% in 2012, Plavix Enjoys Sales Success
April 11, 2013
- Ethical Drug Sales Fall 1.7% in February as Flu Season Slows Down: Crecon Report
April 11, 2013
- Teva Pharma Voluntarily Recalls Enalapril Maleate Tablets
April 11, 2013
- Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
- Fujimoto’s Safety Procedures TERMS Takes Effect April 1, Celgene’s RevMate June 1
April 10, 2013
- Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
- Trazenta Now Stands at Starting Line Without Concurrent Use Restrictions: NBI President Aono
April 10, 2013
- DSP to Solely Develop Therapeutic Cancer Vaccines, Terminating Joint Development Agreement with Chugai
April 10, 2013
- Teva Japan: Pres. Shimada to Retire, Eli Lilly’s Kikushige to Take Helm
April 9, 2013
- Kowa, Daiichi Sankyo to End Livalo, Olmetec Marketing Partnership in June
April 9, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…